0.34

0.00% 0.00

After Hours: .34

Aptevo Therapeutics Inc (APVO)

Overview News Price History Financials Discussions Forecast Stock Split

Aptevo Therapeutics Inc stock is traded at $0.34, with a volume of 1.31M. It is up +0.00% in the last 24 hours and down -66.34% over the past month. Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Previous Close:

$0.34

Open:

$0.33

24h Volume:

1.31M

Relative Volume:

0.47

Market Cap:

$2.44M

Revenue:

$12.99M

Net Income/Loss:

$-23.72M

P/E Ratio:

-0.0035

EPS:

-97.2514

Net Cash Flow:

$-23.28M

1W Performance:

-17.07%

1M Performance:

-66.34%

6M Performance:

-96.22%

1Y Performance:

-98.87%

1-Day Range:

$0.3282

$0.3455

1-Week Range:

$0.3282

$0.4199

52-Week Range:

$0.3282

$32.93

Aptevo Therapeutics Inc Stock (APVO) Company Profile

Name

Aptevo Therapeutics Inc

Sector

Healthcare (1157)

Industry

Biotechnology (676)

Phone

206-838-0500

Address

2401 4TH AVE., SEATTLE, WA

Employee

Twitter

@aptevo

Next Earnings Date

2024-11-12

Latest SEC Filings

APVO's Discussions on Twitter

Compare APVO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APVO Aptevo Therapeutics Inc	0.34	2.44M	12.99M	-23.72M	-23.28M	-97.25
VRTX Vertex Pharmaceuticals Inc	432.00	128.45B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	574.16	65.17B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	542.47	40.09B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	266.86	35.18B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	224.73	27.44B	3.81B	-644.79M	-669.77M	-6.24

Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-18	Initiated	Ladenburg Thalmann	Buy
Oct-05-17	Resumed	Piper Jaffray	Overweight

Aptevo Therapeutics Inc Stock (APVO) Latest News

May 12, 2025

Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World

May 12, 2025

May 10, 2025

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World

May 10, 2025

May 08, 2025

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire

May 08, 2025

Aptevo Therapeutics Provides Program Update for Bispecific APVO7 - GuruFocus

May 08, 2025

Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality - marketscreener.com

May 08, 2025

Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy wit - GuruFocus

May 08, 2025

Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy with APVO711 Update | APVO Stock News - GuruFocus

May 08, 2025

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation | APVO Stock News - GuruFocus

May 08, 2025

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - ACCESS Newswire

May 08, 2025

May 01, 2025

Aptevo Therapeutics announces common stock offering By Investing.com - Investing.com Canada

Apr 29, 2025

Closing Bell Recap: Aptevo Therapeutics Inc (APVO) Ends at 0.61, Reflecting a -9.31 Downturn - DWinneX

Apr 29, 2025

Aptevo Therapeutics announces at-the-market offering - Investing.com Australia

Apr 29, 2025

Apr 28, 2025

APVO stock plunges to 52-week low, touches $0.59 - Investing.com

Apr 28, 2025

APVO stock plunges to 52-week low, touches $0.59 By Investing.com - Investing.com UK

Apr 28, 2025

Aptevo Therapeutics announces at-the-market offering By Investing.com - Investing.com India

Apr 28, 2025

SEC Form 424B4 filed by Aptevo Therapeutics Inc. - Quantisnow

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 26, 2025

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire

Apr 26, 2025

Apr 25, 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire

Apr 25, 2025

Applied Materials Q2 Earnings: Tech Giant's Financial Results Coming May 15 - Stock Titan

Apr 25, 2025

Apr 24, 2025

A look into Aptevo Therapeutics Inc (APVO)’s deeper side - Sete News

Apr 24, 2025

Apr 23, 2025

Aptevo Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com

Apr 23, 2025

Evogene (EVGN) Sees Dramatic Surge in Investor Interest Amid Strategic Moves | APVO Stock News - GuruFocus

Apr 23, 2025

Market Momentum: Aptevo Therapeutics Inc (APVO) Registers a 9.08 Increase, Closing at 0.69 - DWinneX

Apr 23, 2025

Apr 22, 2025

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | APVO Stock News - GuruFocus

Apr 22, 2025

Aptevo Therapeutics Raises Fresh Capital: $2M Direct Offering to Advance Cancer Drug Pipeline - Stock Titan

Apr 22, 2025